The U.S. Food and Drug Administration approved Eloctate for use in adults and children who have hemophilia A.
Eloctate is approved to help control and prevent bleeding episodes, manage bleeding during surgical procedures and prevent or reduce the frequency of bleeding episodes.
Eloctate consists of the coagulation factor VIII molecule — historically known as antihemophilic factor — linked to a protein fragment, Fc, which is found in antibodies. The safety and efficacy of the drug was evaluated in a clinical trial of 164 patients.
New Pathogen-Identification Method Leads to Cost Savings: Study
Kaiser South Sacramento Patients Potentially Exposed to Whooping Cough
Eloctate is approved to help control and prevent bleeding episodes, manage bleeding during surgical procedures and prevent or reduce the frequency of bleeding episodes.
Eloctate consists of the coagulation factor VIII molecule — historically known as antihemophilic factor — linked to a protein fragment, Fc, which is found in antibodies. The safety and efficacy of the drug was evaluated in a clinical trial of 164 patients.
More Articles on Quality:
Despite Guidelines, Antibiotics Prescribed at High Rate for BronchitisNew Pathogen-Identification Method Leads to Cost Savings: Study
Kaiser South Sacramento Patients Potentially Exposed to Whooping Cough
